GC Cell Welcomes New CEO, Announces New Vision: "We Will Become a Global Top-Tier CGT Company"

GC Cell (Jiseusel) declared a new vision, ‘Global Creator of Cell & Gene Therapy,’ symbolizing its ambition to leap forward as a global top-tier cell and gene therapy (CGT) company with the inauguration of its new CEO, James Park.

James Park, CEO of GC Cell, is waving a flag at the vision declaration ceremony held on the 10th at the Mokam Town headquarters in Yongin-si, Gyeonggi Province.
[Photo by GC Cell]

On the 10th, GC Cell announced that all executives and employees gathered at the Mokam Town headquarters in Yongin, Gyeonggi Province, to share the new vision and pledge to advance as a global CGT company. CEO Park proclaimed GC Cell’s new vision, ‘Global Creator of Cell & Gene Therapy,’ and shared with the staff the four core values that constitute the vision: Create, Explore, Link, and Learn.

The core values, represented by the first letters of CELL in English, respectively mean: creating (Create) a healthy life for humanity; exploring (Explore) uncharted paths for health, safety, and the environment; linking (Link) the best technologies and services to the precious value of human life; and learning (Learn) through continuous research and development to become a sustainable company.

Along with the announcement of the new vision, the company officially unveiled a new corporate slogan, ‘Grow CELL. Together.’ CEO Park stated while presenting the slogan, “Let all executives and employees strive for the growth of GC Cell toward the single goal of becoming a global top-tier CGT company. We will achieve change and innovation through a communicative organizational culture and secure future growth engines.”

Additionally, under the theme of the ‘2nd Wave,’ GC Cell outlined specific plans to focus on expanding customers and market share in existing business sectors such as specimen testing and bio-logistics, while concentrating on global market penetration and commercialization R&D in CGT research and development (R&D), production, and contract development and manufacturing organization (CDMO) business sectors to secure future growth engines.

GC Cell conducts R&D in CGT based on natural killer (NK), T, and stem cells, and operates specialized businesses such as CDMO, specimen testing, and bio-logistics. At the regular shareholders’ meeting on the 28th of last month, the company accelerated its global expansion by appointing former Samsung Biologics Vice President James Park as CEO and former K2B Therapeutics Chief Scientific Officer (CSO) Ho-won Kim as Chief Technology Officer (CTO), recruiting global talent.

This content was produced with the assistance of AI translation services.